Prosecution Insights
Last updated: November 04, 2026
Application No. 18/921,166

METHOD TO INCREASE THE CONCENTRATION OF SHATAVARIN I AND SHATAVARIN IV IN EXTRACT FROM ROOTS

Non-Final OA §112
Filed
Oct 21, 2024
Priority
Oct 20, 2023 — IN 202341071648
Examiner
SPAINE, ROBERT FRANKLIN
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Waleria Healthtech Pvt Ltd.
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
8m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
8 granted / 10 resolved
+20.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
56 currently pending
Career history
59
Total Applications
across all art units

Statute-Specific Performance

§101
14.4%
-25.6% vs TC avg
§103
36.6%
-3.4% vs TC avg
§102
8.3%
-31.7% vs TC avg
§112
29.2%
-10.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 10 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-8 are pending and were examined on the merits. Priority Acknowledgment is made of applicant's claim for foreign priority based on an application filed in the Republic of India on October 20th, 2023. It is noted, however, that applicant has not filed a certified copy of the IN202341071648 application as required by 37 CFR 1.55. The current priority date is October 21st, 2024. Information Disclosure Statement The information disclosure statement (IDS) submitted on May 5th, 2026 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Although received documents 2 and 3 in the list of non-patent publications had certain illegible figures, legible copies were retrievable over the internet with trivial effort. Drawings The drawings received on October 21st, 2024 and December 24th, 2024 are objected to because the structures depicted for the compound shatavarin I are inconsistent with the accepted structure in the art for shatavarin I (Shatavarin I. CAS Common Chemistry (CAS RN: 84633-36-3)). Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Objections Claim 1 is objected to because of the following informalities: The term “A. racemosus” appears to be an abbreviation of a genus-species name of an organism. The first mention of A. racemosus in the claims should be in full, non-abbreviated form. Appropriate correction is required. Claims 3-7 are objected to because of the following informalities: for grammatical correctness, the term "mixture" as recited in claims 3-7 should be recited as "a mixture". Appropriate correction is recommended. Claims 4 and 6 are objected to because of the following informalities: the term "and" should be used to complete the list. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 step d) recites repeating steps a)-c) for at least 3 more times to obtain the final residue. However, it is not clear whether repeated step a) comprises adding previously macerated roots of A. racemosus, adding A. racemosus roots that have not been previously macerated, or some combination of these two materials. It is also not clear whether repeated step a) comprises adding roots of A. racemosus to a solvent previously used to extract A. racemosus roots, a solvent not previously used for extraction, or a combination of the two. It is unclear whether the filtrate in claim 1 step c) becomes the solvent, or is somehow included in the solvent, in repeated step a) of claim 1. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-8 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method to extract both shatavarin I and shatavarin IV from roots of A. racemosus using certain solvent combinations (ethanol and water; methanol and water; methanol and chloroform; and ethyl acetate, water, and methanol), does not reasonably provide enablement for a method to extract both shatavarin I and shatavarin IV from roots of A. racemosus using any solvent. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The factors to be considered in determining whether a disclosure meets the enablement requirements of 35 U.S.C. 112, first paragraph, have been described in In re Wands, 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir., 1988). The court in Wands states, “Enablement is not precluded by the necessity for some experimentation, such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. The key word is ‘undue’, not ‘experimentation’” (Wands, 8 USPQ2sd 1404). Clearly, enablement of a claimed invention cannot be predicated on the basis of quantity of experimentation required to make or use the invention. “Whether undue experimentation is needed is not a single, simple factual determination, but rather is a conclusion reached by weighing many factual considerations” (Wands, 8 USPQ2d 1404). Among these factors are: (1) the nature of the invention; (2) the breadth of the claims; (3) the state of the prior art; (4) the predictability or unpredictability of the art; (5) the relative skill of those in the art; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary. (1) The nature of the invention and (2) the breadth of the claims: The claims are drawn to a method to extract shatavarin I and shatavarin IV from roots of A. racemosus, comprising adding roots of A. racemosus to a solvent, as recited in claim 1. Thus, the claims taken together with the specification imply any solvent can extract shatavarin I and shatavarin IV from roots of A. racemosus within the method recited in claim 1. (3) The state of the prior art and (4) the predictability or unpredictability of the art: Jayashree et al. (Industrial Crops and Products 2015, 78, 102-109) recites a method of extracting A. racemosus root material by maceration in methanol: "Briefly A. racemosus root powder was macerated with methanol for one week. The collected extracts were filtered and concentrated to dryness under reduced pressure using a rotary flash evaporator. The final yield obtained was 9% that was used for further experiments" (subheading 2.3). Jayashree et al. further recites "Chemical composition of Asparagaus racemosus root methanolic fraction by LC–ESI–MS/MS analysis: in Table 2. Although Table 2 lists shatavarin I, it does not list shatavarin IV. However, Jayashree et al. would have been aware that shatavarin IV is present in A. racemosus root material, at the time of publication, as Jayashree et al. recites " Hayes et al. (2008) had isolated steroidal saponins such as shatavarin I, IV, V, VI–X, immunoside and schidigera saponin D5 from the roots of A. racemosus" (subheading 3.8, below Table 2). Since the extraction of shatavarin IV from A. racemosus root material through maceration in methanol remains largely unsolved, means for extracting both shatavarin I and IV through the maceration of A. racemosus root material in any solvent is highly unpredictable. (5) The relative skill of those in the art: The relative skill of those in the art is high. Jayashree et al. extracted shatavarin I, V, VII, VIII, IX, and X from Asparagaus racemosus root, as demonstrated by LC–ESI–MS/MS analysis (Jayashree et al., Table 2). Accordingly, one would have turned to the instant disclosure for additional direction and guidance. (6) The amount of direction or guidance presented and (7) the presence or absence of working examples: The specification has provided processes of extracting both shatavarin I and shatavarin IV from roots of A. racemosus using certain solvent combinations: ethanol and water; methanol and water; methanol and chloroform; and ethyl acetate, water, and methanol (Examples 2-4). However, the specification does not provide extracting both shatavarin I and shatavarin IV from roots of A. racemosus using any solvent. (8) The quantity of experimentation necessary: Considering the state of the art as discussed by Jayashree et al. and the high unpredictability and the lack of guidance provided in the specification, one of ordinary skill in the art would be burdened with undue experimentation to extract both shatavarin I and shatavarin IV from roots of A. racemosus using any solvent. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert F Spaine whose telephone number is (571)272-9099. The examiner can normally be reached 8:00 AM - 4:00 PM United States Eastern Time, Monday-Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at (571) 272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /R.F.S./Examiner, Art Unit 1655 /ANAND U DESAI/Supervisory Patent Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Oct 21, 2024
Application Filed
Sep 30, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773438
METHOD OF EXTRACTION OF PROANTHOCYANIDINS COMPOUND FROM PINE BARK OF PINUS ROXBURGHII
2y 11m to grant Granted Oct 27, 2026
Patent 12751986
COMPOSITION FOR INHIBITING PROLIFERATION OF TUMOR COMPRISING RUBUS COREANUS EXTRACT AS EFFECTIVE COMPONENT
2y 10m to grant Granted Oct 06, 2026
Patent 12728144
Composition Based on Natural Ingredients and Use of the Composition for Improving Mental Health
4y 2m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 3 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
80%
With Interview (+0.0%)
2y 9m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 10 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month